康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603590 康辰药业

已收盘 09-30 15:00:00

{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":53.8,"timestamp":1759215600000,"preClose":53.43,"halted":0,"volume":2160200,"delay":0,"changeRate":0.0069,"floatShares":158000000,"shares":159000000,"eps":0.3393,"marketStatus":"已收盘","change":0.37,"latestTime":"09-30 15:00:00","open":53.67,"high":54.43,"low":52.31,"amount":115000000,"amplitude":0.0397,"askPrice":53.8,"askSize":168,"bidPrice":53.73,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.3393,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1759973400000},"marketStatusCode":5,"adr":0,"adjPreClose":53.43,"symbolType":"stock","openAndCloseTimeList":[[1759195800000,1759203000000],[1759208400000,1759215600000]],"highLimit":58.77,"lowLimit":48.09,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":159356477,"isCdr":false,"pbRate":2.75,"roa":"--","peRate":158.561745,"roe":"2.87%","epsLYR":0.27,"committee":0.213187,"marketValue":8573000000,"turnoverRate":0.0137,"status":0,"floatMarketCap":8512000000},"requestUrl":"/m/hq/s/603590","defaultTab":"news","newsList":[{"id":"2571712349","title":"康辰药业：9月29日高管牛战旗减持股份合计8.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2571712349","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571712349?lang=zh_cn&edition=full","pubTime":"2025-09-30 19:01","pubTimestamp":1759230083,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月30日市场公开信息、上市公司公告及交易所披露数据整理，康辰药业最新董监高及相关人员股份变动情况：2025年9月29日公司董事,总裁牛战旗共减持公司股份8.75万股，占公司总股本为0.0549%。康辰药业近半年内的董监高及核心技术人员增减持详情如下：康辰药业的高管列表及最新持股情况如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为63.18。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000033710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2571387008","title":"康辰药业最新公告：KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌获得临床试验通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387008","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571387008?lang=zh_cn&edition=full","pubTime":"2025-09-29 19:20","pubTimestamp":1759144809,"startTime":"0","endTime":"0","summary":"康辰药业(603590.SH)公告称，公司收到国家药品监督管理局核准签发的化学1类创新药KC1036片关于“KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌”的临床试验通知书，并将于近期开展临床试验。KC1036是公司自主研发的化学药品1类创新药，通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。目前已有超300例受试者入组KC1036临床研究，现有临床研究结果显示了突出的抗肿瘤活性、以及良好的安全性和耐受性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900029282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2569827661","title":"康辰药业（603590）79.6万股限售股将于9月22日解禁，占总股本0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569827661","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569827661?lang=zh_cn&edition=full","pubTime":"2025-09-22 08:02","pubTimestamp":1758499361,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，康辰药业于9月22日将有79.6万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.5%。最近一年内，该股累计解禁93.61万股，占总股本的0.59%。本次解禁后，公司还有113.3万股限售股份，占总股本0.71%。康辰药业主营业务：公司是一家以创新药研发为核心、以临床需求为导向,集研发、生产和销售于一体的创新型制药企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2569249379","title":"每周股票复盘：康辰药业（603590）2023年限制性股票解除限售796,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569249379","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569249379?lang=zh_cn&edition=full","pubTime":"2025-09-21 05:12","pubTimestamp":1758402738,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，康辰药业报收于56.35元，较上周的54.93元上涨2.59%。本周，康辰药业9月16日盘中最高价报61.8元。本次解除限售的限制性股票数量为796,000股，占公司总股本的0.50%，上市流通日期为2025年9月22日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2567103680","title":"康辰药业80万股限制性股票将于9月22日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2567103680","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567103680?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:25","pubTimestamp":1758011100,"startTime":"0","endTime":"0","summary":"9月16日，康辰药业（603590）发布公告，关于公司2023年限制性股票激励计划首次授予部分第二个解除限售期解除限售暨上市的相关事项。本次股票上市流通总数为80万股，上市流通日期为2025年9月22日。此次解除限售的限制性股票数量为80万股，占公司目前总股本的0.50%。解除限售的激励对象人数为18人。解除限售后，公司股本结构发生变化，限售流通股由193万股变更为113万股，无限售流通股由1.57亿股变更为1.58亿股。2025年中期，康辰药业实现收入4.61亿元，归母净利润9105万元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-16/doc-infqstck0700052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2566864779","title":"股市必读：康辰药业（603590）9月10日收盘跌5.06%，主力净流出1764.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566864779","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566864779?lang=zh_cn&edition=full","pubTime":"2025-09-11 01:34","pubTimestamp":1757525652,"startTime":"0","endTime":"0","summary":"截至2025年9月10日收盘，康辰药业报收于52.17元，下跌5.06%，换手率3.05%，成交量4.81万手，成交额2.56亿元。来自资金流向：9月10日主力资金净流出1764.95万元，占总成交额6.9%，散户资金净流入3391.36万元。交易信息汇总股价提醒9月10日康辰药业收盘报52.17元，跌5.06%，当日成交480.68万元。该股已连续3日下跌。前10个交易日主力资金累计净流入6990.54万元，股价累计上涨4.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100001488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2566858647","title":"太平洋：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2566858647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566858647?lang=zh_cn&edition=full","pubTime":"2025-09-10 08:35","pubTimestamp":1757464529,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对康辰药业进行研究并发布了研究报告《康辰药业：苏灵保持稳健增长，KC1086已开始入组》，给予康辰药业买入评级。2025年8月22日，该试验已在首研单位中国医学科学院肿瘤医院完成首例受试者入组。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为63.18。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000006811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","603590"],"gpt_icon":0},{"id":"2565543635","title":"每周股票复盘：康辰药业（603590）因股价异动登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2565543635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565543635?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:56","pubTimestamp":1757192173,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，康辰药业报收于56.93元，较上周的56.17元上涨1.35%。本周，康辰药业9月2日盘中最高价报65.5元。本周关注点交易信息汇总：康辰药业因连续两日收盘价涨幅偏离值超20%登上龙虎榜。股本股东变化：股东刘建华拟减持不超过公司总股本3%的股份。北京康辰药业股份有限公司董事会2025年9月2日康辰药业股东减持股份计划公告北京康辰药业股份有限公司股东刘建华计划减持股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2565306995","title":"康辰药业(603590.SH)：KC1036纳入药审中心“星光计划”试点项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2565306995","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565306995?lang=zh_cn&edition=full","pubTime":"2025-09-05 15:40","pubTimestamp":1757058005,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康辰药业 发布公告，近日，公司1类创新药KC1036被国家药品监督管理局药品审评中心纳入“儿童抗肿瘤药物研发鼓励试点计划”。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。本次公司KC1036作为首批首个入选“星光计划”的创新药品种，代表药审中心对KC1036创新性和在青少年尤文肉瘤患者获益性上的认可，更推动公司关注中国儿童肿瘤患者的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2565537047","title":"康辰药业(603590.SH)控股股东拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2565537047","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565537047?lang=zh_cn&edition=full","pubTime":"2025-09-05 15:37","pubTimestamp":1757057871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康辰药业(603590.SH)发布公告，自公告披露之日起15个交易日后的3个月内(根据法律法规禁止减持的期间除外)，公司控股股东刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式减持其所持有的公司股份，合计不超过478.07万股，即不超过规定的公司股份总数的3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2564484203","title":"康辰药业（603590）19万股限售股将于9月4日解禁，占总股本0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564484203","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564484203?lang=zh_cn&edition=full","pubTime":"2025-09-04 08:05","pubTimestamp":1756944303,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，康辰药业于9月4日将有19.0万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.12%。最近一年内，该股累计解禁74.61万股，占总股本的0.47%。本次解禁后，公司还有192.9万股限售股份，占总股本1.21%。康辰药业主营业务：公司是一家以创新药研发为核心、以临床需求为导向,集研发、生产和销售于一体的创新型制药企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400005171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2564384731","title":"股市必读：康辰药业（603590）9月2日收盘跌7.17%，主力净流出6368.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564384731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564384731?lang=zh_cn&edition=full","pubTime":"2025-09-03 01:37","pubTimestamp":1756834629,"startTime":"0","endTime":"0","summary":"截至2025年9月2日收盘，康辰药业报收于57.36元，下跌7.17%，换手率7.49%，成交量11.77万手，成交额7.08亿元。当日关注点来自交易信息汇总：9月2日康辰药业收盘报57.36元，跌7.17%，主力资金前10个交易日累计净流出8933.72万元，同期股价累计上涨3.51%。来自资金流向：9月2日主力资金净流出6368.13万元，占总成交额8.99%，散户资金净流入3102.01万元。交易信息汇总9月2日康辰药业收盘报57.36元，跌7.17%，当日成交1177.31万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2564764816","title":"康辰药业：不存在应披露而未披露的重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2564764816","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564764816?lang=zh_cn&edition=full","pubTime":"2025-09-01 18:18","pubTimestamp":1756721909,"startTime":"0","endTime":"0","summary":"康辰药业9月1日晚间发布股票交易异动公告称，经自查，并书面征询控股股东、实控人，截至目前，除公司已披露事项外，不存在应披露而未披露的重大信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/09/01181852851070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2564813950","title":"9月1日康辰药业（603590）龙虎榜数据：机构净买入5987.36万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2564813950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564813950?lang=zh_cn&edition=full","pubTime":"2025-09-01 17:28","pubTimestamp":1756718908,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年9月1日公布的交易公开信息显示，康辰药业因非ST、*ST和S证券连续三个交易日内收盘价格涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年9月1日收盘，康辰药业报收于61.79元，上涨10.01%，已连续涨停2天，换手率5.0%，成交量7.86万手，成交额4.8亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入5987.36万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100023998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2563002884","title":"每周股票复盘：康辰药业（603590）2025年Q2扣非净利增50.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563002884","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563002884?lang=zh_cn&edition=full","pubTime":"2025-08-31 03:00","pubTimestamp":1756580436,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，康辰药业报收于56.17元，较上周的52.85元上涨6.28%。股本股东变化截至2025年6月30日，康辰药业股东户数为9970户，较3月31日减少1210户，减幅10.82%。业绩披露要点康辰药业2025年中报显示，主营收入4.61亿元，同比上升13.79%；归母净利润9104.61万元，同比上升14.95%；扣非净利润9625.74万元，同比上升29.21%。其中2025年第二季度单季度主营收入2.49亿元，同比上升20.93%；单季度归母净利润4654.87万元，同比上升23.97%；单季度扣非净利润5235.78万元，同比上升50.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2563091136","title":"异动快报：康辰药业（603590）8月29日10点17分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2563091136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563091136?lang=zh_cn&edition=full","pubTime":"2025-08-29 10:20","pubTimestamp":1756434044,"startTime":"0","endTime":"0","summary":"证券之星8月29日盘中消息，10点17分康辰药业触及涨停板。目前价格56.17，上涨10.01%。其所属行业生物制品目前下跌。该股为医药，创新药，创投概念热股，当日医药概念上涨0.42%，创新药概念上涨0.4%。8月28日的资金流向数据方面，主力资金净流入3371.92万元，占总成交额10.27%，游资资金净流入297.37万元，占总成交额0.91%，散户资金净流出3669.29万元，占总成交额11.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900013386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2563124063","title":"股市必读：康辰药业中报 - 第二季度单季净利润同比增长23.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563124063","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563124063?lang=zh_cn&edition=full","pubTime":"2025-08-29 03:07","pubTimestamp":1756408071,"startTime":"0","endTime":"0","summary":"截至2025年8月28日收盘，康辰药业报收于51.06元，上涨3.17%，换手率4.11%，成交量6.47万手，成交额3.28亿元。来自业绩披露要点：2025年第二季度扣非净利润同比上升50.28%，增速显著提升。股本股东变化股东户数变动近日康辰药业披露，截至2025年6月30日公司股东户数为9970.0户，较3月31日减少1210.0户，减幅为10.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900001385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"gpt_icon":0},{"id":"2562176397","title":"康辰药业最新公告：高管牛战旗拟减持不超过8.75万公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2562176397","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562176397?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:32","pubTimestamp":1756290776,"startTime":"0","endTime":"0","summary":"康辰药业(603590.SH)公告称，公司高级管理人员牛战旗因自身资金需求，计划自本公告披露之日起15个交易日后的3个月内，通过集中竞价方式减持其所持公司无限售条件流通股不超过87,500股。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700039660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2562712507","title":"康辰药业：2025年上半年净利润同比增长14.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562712507","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562712507?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:12","pubTimestamp":1756289550,"startTime":"0","endTime":"0","summary":"康辰药业公告，2025年上半年营业收入4.61亿元，同比增长13.79%。净利润9104.61万元，同比增长14.95%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/27181252745575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603590"],"gpt_icon":0},{"id":"2562756000","title":"康辰药业股价下跌4.34% 临时股东大会明日召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2562756000","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562756000?lang=zh_cn&edition=full","pubTime":"2025-08-27 01:54","pubTimestamp":1756230859,"startTime":"0","endTime":"0","summary":"截至2025年8月26日收盘，康辰药业股价报50.65元，较前一交易日下跌2.30元，跌幅4.34%。当日成交额2.40亿元，换手率2.97%。康辰药业主营业务为创新药物的研发、生产和销售，产品涵盖抗肿瘤、血液系统疾病等领域。公司所属概念板块包括生物制品、创新药、专精特新等。消息面上，康辰药业将于2025年8月27日召开第二次临时股东大会，审议变更注册资本及修订公司章程等议案。资金流向方面，8月26日主力资金净流出3071.49万元，近五日累计净流出1.37亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/27015452719365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603590","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1759969713689,"stockEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":-0.0422},{"period":"3month","weight":0.6818},{"period":"6month","weight":1.0157},{"period":"1year","weight":1.2116},{"period":"ytd","weight":1.332}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.1239},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.1584}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9970人(较上一季度减少10.82%)","perCapita":"15869股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15935万元","survey":"　　北京康辰药业股份有限公司的主营业务是化学药品制剂制造。公司的主要产品是“苏灵”、“密盖息”。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}